Literature DB >> 16856889

Effects of bortezomib on pro-inflammatory cytokine levels and transfusion dependency in a patient with multicentric Castleman disease.

Georg Hess, Volker Wagner, Andreas Kreft, Claus Peter Heussel, Christoph Huber.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16856889     DOI： 10.1111/j.1365-2141.2006.06212.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  15 in total

1.  HHV-8-associated multicentric Castleman's disease in HIV-negative patient: a novel therapy for an orphan disease.

Authors:  Maria M Sbenghe; Emmanuel Besa; Amit Mahipal; Alina Dulau Florea; Paul Bray; Jaime Caro
Journal:  Oncologist       Date:  2012

Review 2.  Novel insights and therapeutic approaches in idiopathic multicentric Castleman disease.

Authors:  David C Fajgenbaum
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2018-11-30

3.  Analysis of clinical characteristics and prognosis factors of 71 cases with HIV-negative Castleman's disease: hypoproteinemia is an unfavorable prognostic factor which should be treated appropriately.

Authors:  Xuan Lan; Zhaoming Li; Mingzhi Zhang
Journal:  J Cancer Res Clin Oncol       Date:  2018-05-07       Impact factor: 4.553

Review 4.  Castleman's disease: from basic mechanisms to molecular therapeutics.

Authors:  Hazem E El-Osta; Razelle Kurzrock
Journal:  Oncologist       Date:  2011-03-25

Review 5.  Castleman's disease--a two compartment model of HHV8 infection.

Authors:  Klaus-Martin Schulte; Nadia Talat
Journal:  Nat Rev Clin Oncol       Date:  2010-07-06       Impact factor: 66.675

Review 6.  Novel insights and therapeutic approaches in idiopathic multicentric Castleman disease.

Authors:  David C Fajgenbaum
Journal:  Blood       Date:  2018-11-29       Impact factor: 22.113

Review 7.  Multicentric Castleman's disease presenting with multiple nodes in lungs: a case report and literature review.

Authors:  Xuefeng Sun; Bing Han
Journal:  Int J Hematol       Date:  2008-09-26       Impact factor: 2.490

Review 8.  Biologic Agents in the Treatment of Multicentric Castleman Disease.

Authors:  Konstantinos Kapriniotis; Savvas Lampridis; Sofoklis Mitsos; Davide Patrini; David R Lawrence; Nikolaos Panagiotopoulos
Journal:  Turk Thorac J       Date:  2018-10-01

9.  Stromal cells in bone marrow play important roles in pro-inflammatory cytokine secretion causing fever following bortezomib administration in patients with multiple myeloma.

Authors:  Dai Maruyama; Takashi Watanabe; Yuji Heike; Kumiko Nagase; Noriko Takahashi; Satoshi Yamasaki; Fusako Waki; Hiroki Yokoyama; Sung-Won Kim; Yukio Kobayashi; Shin Aizawa; Kensei Tobinai
Journal:  Int J Hematol       Date:  2008-11-07       Impact factor: 2.490

Review 10.  Clinical challenges associated with bortezomib therapy in multiple myeloma and Waldenströms Macroglobulinemia.

Authors:  Jacob P Laubach; Constantine S Mitsiades; Aldo M Roccaro; Irene M Ghobrial; Kenneth C Anderson; Paul G Richardson
Journal:  Leuk Lymphoma       Date:  2009-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.